Overview

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
MULTICENTERS. Uncontrolled and open phase II study. Evaluation of the effectiveness of a treatment associating 5 Azacytidine,Valproic acid ,Retinoic Acid at subjects-reached of syndromes myelodysplasia and acute MYELOID leukaemia Hematological response at 6 months Uncontrolled prospective cohort.
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Azacitidine
Tretinoin
Valproic Acid